- Title
- Randomized Double-Blind Phase 2 Trial of 3 Doses of TAS-108 in Patients With Advanced or Metastatic Postmenopausal Breast Cancer
- Creators
- Aman BUZDAR - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesCharles VOGEL - Internal Medicine, Oncology, Lynn Cancer Institute, Boca Raton, Florida, United StatesLee SCHWARTZBERG - Medical Oncology, Hematology, The West Cancer Clinic, Memphis, Tennessee, United StatesAugust GARIN - Department of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow, Russia, United StatesAlejandra PEREZ - Department of Hematology/Oncology, Memorial Regional Hospital, Breast Cancer Center, Hollywood, Florida, United StatesJames INGLE - Department of Breast Cancer and Oncology, Mayo Clinic, Rochester, Minnesota, United StatesMichele HOUGHTON - Global Senior Director, Clinical Operations, Taiho Pharma USA, Inc, Princeton, New Jersey, United StatesChristopher ZERGEBEL - Global Senior Director, Project Management, Taiho Pharma USA, Inc, Princeton, New Jersey, United StatesBill KIMBALL - Quintiles Global Biostatistics, Quintiles, Inc, Morrisville, North Carolina, United States
- Publication Details
- Cancer, Vol.118(13), pp.3244-3253
- Publisher
- Wiley-Blackwell; Hoboken, NJ
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 22045595
- Record Identifier
- 991031560952502976
Journal article
Randomized Double-Blind Phase 2 Trial of 3 Doses of TAS-108 in Patients With Advanced or Metastatic Postmenopausal Breast Cancer
Cancer, Vol.118(13), pp.3244-3253
2012
PMID: 22045595
Metrics
16 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.141 Hormone Therapy
- 1.141.244 Tamoxifen
- Web Of Science research areas
- Oncology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites